Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C
| Autor: | Mitsuteru Natsuizaka, Miki Tateyama, Hiromasa Horimoto, Keisuke Shinada, Seiji Tsunematsu, Goki Suda, Atsushi Nagasaka, Mineo Kudo, Machiko Umemura, Takaaki Izumi, Katsumi Terashita, Koji Ogawa, Takuya Sho, Ken Furuya, Yoko Tsukuda, Fumiyuki Sato, Masato Nakai, Naoya Sakamoto, Jun Konno, Megumi Kimura, Yoshiya Yamamoto, Kazushi Yamasaki, Tomoe Kobayashi, Kenichi Morikawa |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Pyrrolidines Daclatasvir Cirrhosis Combination therapy medicine.medical_treatment 030232 urology & nephrology Antiviral Agents 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Renal Dialysis Internal medicine Asunaprevir Humans Medicine Prospective Studies Renal Insufficiency Intensive care medicine Adverse effect Aged Sulfonamides business.industry Imidazoles Gastroenterology virus diseases Valine Hepatitis C Chronic Middle Aged Hepatology Isoquinolines Nosocomial infection control medicine.disease digestive system diseases chemistry Hemodialysis HCV Drug Therapy Combination Female 030211 gastroenterology & hepatology Carbamates business medicine.drug |
| Zdroj: | Journal of gastroenterology. 51(7):733-740 |
| ISSN: | 0944-1174 0000-1635 |
| Popis: | Background: HCV infection in chronic hemodialysis patients is high, has a poor prognosis and high risk of renal graft failure, and requires nosocomial infection control measures. However, options of anti-HCV therapy in such patients are limited and unsatisfactory. In this study, we report effectiveness and safety of HCV-NS5A-inhibitor daclatasvir (DCV) and protease-inhibitor asunaprevir (ASV) combination therapy for hemodialysis patients with HCV infection. Methods: This study was registered at the UMIN Clinical Trials Registry as UMIN000016355. Thirty-four dialysis patients were treated with DCV/ASV combination therapy between January 2015 and November 2015. Of those, 21 patients who were followed more than 12 weeks after treatment ended were included. We evaluated the 12-week sustained virologic response (SVR12) and adverse events during treatment. Results: Of the 21 patients, four had compensated liver cirrhosis and three had resistance-associated variant of NS5A (NS5A RAVs)-Y93H at baseline. Overall, total of 95.5 % (20/21) of the patients achieved SVR12. Of note, all patients with cirrhosis or NS5A RAVs achieved SVR12. One relapser patient at 4 weeks post-treatment had NS3 D168E RAVs at baseline. A total of 20 patients (95.5 %) completed the 24-week therapy. One patient discontinued treatment at week 12 due to ALT elevations and achieved SVR12. Conclusions: DAV and ASV combination therapy for chronic hemodialysis patients with HCV infection was highly effective and well tolerated, even in elderly patients and patients with liver cirrhosis and NS5A-RAVs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink